Lau G, Sangro B, Cheng AL, Kudo M, et al. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. Hepatology 2025 May 16. doi: 10.1097/HEP.0000000000001385.
PMID: 40384092